PRINCETON, N.J., May 16 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX) today announced that Howard H. Pien will join the company as
President and Chief Executive Officer and member of the Medarex Board of
Directors effective June 14, 2007. Mr. Pien will succeed Irwin Lerner who
has served as the Company's Interim President and Chief Executive Officer
since November 2006. Mr. Lerner will continue in his role as Chairman of
the Board of Medarex.
"We are thoroughly delighted to have Howard join Medarex as our Chief
Executive," commented Mr. Lerner. "No one could be more qualified to lead
our company to the next level of its development. Howard has broad and deep
biopharmaceutical industry expertise, encompassing general management,
finance, commercial and manufacturing operations, deal-making and
partnerships -- an impressive background which blends perfectly with the
Medarex business profile."
"I am delighted to join Medarex at this time and honored to work with
its top-notch team," said Mr. Pien. "I believe that Medarex is a
well-respected company in the industry and that the potential opportunities
ahead for the company are nearly boundless. I look forward to being a part
of the company as it continues to grow and strengthen its position in the
field of antibody therapeutics."
Mr. Pien brings to Medarex more than 20 years of industry experience.
He was most recently President and Chief Executive Officer of Chiron
Corporation until April 2006 when it was acquired by Novartis. He joined
Chiron from GlaxoSmithKline, where he served as President of the
International Pharmaceuticals business. Previous to that, Mr. Pien held the
position of President, Pharmaceuticals for SmithKline Beecham. He also
previously worked at Abbott Laboratories and at Merck & Co. where he held
positions in sales, market research, licensing and product management. Mr.
Pien earned a B.S. from the Massachusetts Institute of Technology in 1979
and an M.B.A. from Carnegie-Mellon University in 1981.
Medarex is a biopharmaceutical company focused on the discovery,
development and potential commercialization of fully human antibody-based
therapeutics to treat life-threatening and debilitating diseases, including
cancer, inflammation, autoimmune disorders and infectious diseases. Medarex
applies its UltiMAb(R) technology and product development and clinical
manufacturing experience to generate, support and potentially commercialize
a broad range of fully human antibody product candidates for itself and its
partners. More than 30 of these therapeutic product candidates derived from
Medarex technology are in human clinical testing or have had INDs submitted
for such trials, with six of the most advanced product candidates currently
in Phase III clinical trials. Medarex is committed to building value by
developing a diverse pipeline of antibody products to address the world's
unmet healthcare needs. For more information about Medarex, visit its
website at http://www.medarex.com.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks
of Medarex, Inc. All rights are reserved.
SOURCE Medarex, Inc.
 back to top
Related links:
http://www.medarex.com
http://www.prnewswire.com/comp/108265.html/
CONTACT:
Laura S. Choi, Investor Relations,
+1-609-430-2880, x2216, or Jean Mantuano, Corporate
Communications (media), +1-609-430-2880, x2221, both of Medarex,
Inc.
|
